Legend Biotech Corporation
LEGN
$35.04
$0.340.98%
| Weiss Ratings | LEGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | LEGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | LEGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.52 | |||
| Price History | LEGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -5.32% | |||
| 30-Day Total Return | -6.41% | |||
| 60-Day Total Return | -15.89% | |||
| 90-Day Total Return | -20.27% | |||
| Year to Date Total Return | 0.89% | |||
| 1-Year Total Return | -45.06% | |||
| 2-Year Total Return | -25.06% | |||
| 3-Year Total Return | 2.31% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -49.88% | |||
| 52-Week Low % Change | 15.01% | |||
| Price | LEGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $69.24 | |||
| 52-Week Low Price | $30.17 | |||
| 52-Week Low Price (Date) | Jan 13, 2025 | |||
| 52-Week High Price (Date) | Mar 13, 2024 | |||
| Valuation | LEGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 6.37B | |||
| Enterprise Value | 5.50B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.82 | |||
| Earnings Per Share Growth | -36.04% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 6.11 | |||
| Price/Book (Q) | 2.85 | |||
| Enterprise Value/Revenue (TTM) | 10.57 | |||
| Price | $35.04 | |||
| Enterprise Value/EBITDA (TTM) | -16.15 | |||
| Enterprise Value/EBIT | -15.66 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | LEGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 91.64M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | LEGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 732 317 5050 | |||
| Address | 2101 Cottontail Lane Somerset, NJ 08873 | |||
| Website | www.legendbiotech.com | |||
| Country | United States | |||
| Year Founded | 2014 | |||
| Profitability | LEGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -67.52% | |||
| Profit Margin | -66.92% | |||
| Management Effectiveness | LEGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -12.28% | |||
| Return on Equity | -- | |||
| Income Statement | LEGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 514.11M | |||
| Total Revenue (TTM) | 520.18M | |||
| Revenue Per Share | $5.68 | |||
| Gross Profit (TTM) | -87.72M | |||
| EBITDA (TTM) | -340.56M | |||
| EBIT (TTM) | -351.24M | |||
| Net Income (TTM) | -348.13M | |||
| Net Income Avl. to Common (TTM) | -348.13M | |||
| Total Revenue Growth (Q YOY) | 66.86% | |||
| Earnings Growth (Q YOY) | -101.46% | |||
| EPS Diluted (TTM) | -3.82 | |||
| EPS Diluted Growth (Q YOY) | -99.53% | |||
| Balance Sheet | LEGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.21B | |||
| Cash Per Share (Q) | $13.23 | |||
| Total Current Assets (Q) | 1.35B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.12B | |||
| Current Ratio (Q) | 4.984 | |||
| Book Value Per Share (Q) | $12.17 | |||
| Total Assets (Q) | 1.74B | |||
| Total Current Liabilities (Q) | 270.89M | |||
| Total Debt (Q) | 346.59M | |||
| Total Liabilities (Q) | 619.72M | |||
| Total Common Equity (Q) | 1.12B | |||
| Cash Flow | LEGN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -355.19M | |||
| Cash from Financing (TTM) | 6.96M | |||
| Net Change in Cash (TTM) | -504.19M | |||
| Levered Free Cash Flow (TTM) | -153.82M | |||
| Cash from Operations (TTM) | -157.60M | |||
